Donanemab in Early Alzheimer’s Disease

Phase II study of 257 pts found better score for cognition and ability to perform activities of daily living with donanemab (antibody that targets amyloid-β peptide) vs placebo at 76 weeks (baseline change in Integrated Alzheimer’s Disease Rating Scale: −6.86 vs −10.06; P=0.04).

Source:

New England Journal of Medicine